ExpreS2ion Biotech Holding AB (publ)
EXPRS2
Rank in Stocks
#33781
Based in Horsholm, Denmark, ExpreS2ion Biotech Holding AB, along with its... Based in Horsholm, Denmark, ExpreS2ion Biotech Holding AB, along with its subsidiary ExpreS2ion Biotechnologies, specializes in creating and manufacturing complex proteins for use in vaccines and diagnostic products. The company's development pipeline includes a capsid virus-like particle COVID-19 vaccine, an influenza vaccine, and a breast cancer vaccine, all of which are currently undergoing Phase II clinical trials. ExpreS2ion is also engaged in developing a malaria vaccine. Furthermore, the company extends its reach by licensing its proprietary ExpreS2 platform to various research organizations and pharmaceutical businesses. ExpreS2ion Biotech Holding AB commenced operations in 2015.
Share Price
$0.09325189
Last synced: 2026-11-09
Market Cap
$237.89K
Change (1 day)
-0.60%
Change (1 year)
-94.75%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade ExpreS2ion Biotech Holding AB (publ) (EXPRS2)
Category
Healthcare
P/E ratio for ExpreS2ion Biotech Holding AB (publ) (EXPRS2)
P/E ratio as of November 2026 TTM: -0.14
According to ExpreS2ion Biotech Holding AB (publ)'s latest financial reports and stock price, its current price-to-earnings ratio (TTM) is -0.14. At the end of 2025 the company had a P/E ratio of -1.19.
P/E ratio history for ExpreS2ion Biotech Holding AB (publ) from 2013 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | -0.14 | -88.51% |
| 2025 | -1.19 | 22.85% |
| 2024 | -0.97 | -9.26% |
| 2023 | -1.07 | -79.75% |
| 2022 | -5.26 | -80.01% |
| 2021 | -26.31 | 310.53% |
| 2020 | -6.41 | 74.77% |
| 2019 | -3.67 | -32.21% |
| 2018 | -5.41 | -56.70% |
| 2017 | -12.49 | 33.74% |
| 2016 | -9.34 | 105.42% |
| 2015 | -4.55 | -103.31% |
| 2014 | 137.39 | 146.56% |
| 2013 | 55.72 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 32.27 | -23,704.90% |
US
|
|
| -27.78 | 20,225.16% |
US
|
|
| -26.70 | 19,428.60% |
AU
|
|
| 24.36 | -17,922.68% |
BE
|
|
| 42.44 | -31,148.06% |
NL
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.
Questions about ExpreS2ion Biotech Holding AB (publ)'s P/E ratio
What is ExpreS2ion Biotech Holding AB (publ)'s P/E ratio?
ExpreS2ion Biotech Holding AB (publ)'s P/E ratio is -0.14, as of Nov 2026.
What was ExpreS2ion Biotech Holding AB (publ)'s P/E ratio in 2025?
In 2025, ExpreS2ion Biotech Holding AB (publ)'s P/E ratio was -1.19, compared with -0.97 in 2024.
How has ExpreS2ion Biotech Holding AB (publ)'s P/E ratio changed since 2020?
From 2020 to 2025, ExpreS2ion Biotech Holding AB (publ)'s P/E ratio was highest in 2024 (-0.97) and lowest in 2021 (-26.31).
How does ExpreS2ion Biotech Holding AB (publ)'s P/E ratio compare with similar companies?
ExpreS2ion Biotech Holding AB (publ)'s P/E ratio (-0.14) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with 42.44.